6CM
FULC icon

683 Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

683 Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-46,778
Closed -$316K – 177
2023
Q4 		$316K Buy
+46,778
New +$208K 0.03% 114

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

683 Capital Management's FULC Position: Q1 2024 in Review

683 Capital Management sold out of Fulcrum Therapeutics (FULC) in Q1 2024, closing a stake of 46,778 shares — an estimated $316K sold.

683 Capital Management first reported a position in FULC in Q4 2023 and held it in 1 quarter. The position peaked at $316K in Q4 2023. 126 funds tracked by Wall St. Rank hold FULC as of Q1 2024.

  • 683 Capital Management reported no remaining Fulcrum Therapeutics position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 46,778 Fulcrum Therapeutics shares in Q1 2024, an estimated $316K.
  • 683 Capital Management first reported a position in Fulcrum Therapeutics in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's Fulcrum Therapeutics position peaked at $316K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.